Leyre Bento, Antonio Gutiérrez, Carmen Martínez, María Consejo Ortí Verdet, Marina Sorribes, Ana Carolina Caballero, Marta Peña, Ariadna Pérez, Ana Jiménez-Ubieto, Lucía Medina, Mariana Bastos-Oreiro, Paula Fernández Caldas-González, Belén Navarro, Isabel Salcedo, Pau Abrisqueta, Ignacio Español, Javier Cornago, Fernando Martín-Moro, Lucía García, Pilar Gómez, María Rosario Varela, María Puente, Joud Zanabili, Teresa Zudaire, Izaskun Zeberio, Raquel Del Campo, Leslie González, Pedro González, Cristina Blázquez, Jordina Rovira, Marta Sitges, Mireia Franch-Sarto, Almudena Cabero, Alberto Mussetti, Juan Montoro, Antonia Sampol, Anna Sureda, Dolores Caballero, Alejandro Martín García-Sancho
{"title":"自体干细胞移植治疗复发/难治性大B细胞淋巴瘤：多中心GETH-TC/GELTAMO研究","authors":"Leyre Bento, Antonio Gutiérrez, Carmen Martínez, María Consejo Ortí Verdet, Marina Sorribes, Ana Carolina Caballero, Marta Peña, Ariadna Pérez, Ana Jiménez-Ubieto, Lucía Medina, Mariana Bastos-Oreiro, Paula Fernández Caldas-González, Belén Navarro, Isabel Salcedo, Pau Abrisqueta, Ignacio Español, Javier Cornago, Fernando Martín-Moro, Lucía García, Pilar Gómez, María Rosario Varela, María Puente, Joud Zanabili, Teresa Zudaire, Izaskun Zeberio, Raquel Del Campo, Leslie González, Pedro González, Cristina Blázquez, Jordina Rovira, Marta Sitges, Mireia Franch-Sarto, Almudena Cabero, Alberto Mussetti, Juan Montoro, Antonia Sampol, Anna Sureda, Dolores Caballero, Alejandro Martín García-Sancho","doi":"10.1182/bloodadvances.2024015415","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>We performed a retrospective multicenter study including 791 patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as ≥3rd line (HR, 1.81; 95% CI, 1.42-2.31; P < .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P < .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P < .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as ≥3rd line (HR, 1.77; 95% CI, 1.32-2.37; P < .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P < .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P < .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":" ","pages":"3281-3292"},"PeriodicalIF":7.4000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study.\",\"authors\":\"Leyre Bento, Antonio Gutiérrez, Carmen Martínez, María Consejo Ortí Verdet, Marina Sorribes, Ana Carolina Caballero, Marta Peña, Ariadna Pérez, Ana Jiménez-Ubieto, Lucía Medina, Mariana Bastos-Oreiro, Paula Fernández Caldas-González, Belén Navarro, Isabel Salcedo, Pau Abrisqueta, Ignacio Español, Javier Cornago, Fernando Martín-Moro, Lucía García, Pilar Gómez, María Rosario Varela, María Puente, Joud Zanabili, Teresa Zudaire, Izaskun Zeberio, Raquel Del Campo, Leslie González, Pedro González, Cristina Blázquez, Jordina Rovira, Marta Sitges, Mireia Franch-Sarto, Almudena Cabero, Alberto Mussetti, Juan Montoro, Antonia Sampol, Anna Sureda, Dolores Caballero, Alejandro Martín García-Sancho\",\"doi\":\"10.1182/bloodadvances.2024015415\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Abstract: </strong>We performed a retrospective multicenter study including 791 patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as ≥3rd line (HR, 1.81; 95% CI, 1.42-2.31; P < .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P < .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P < .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as ≥3rd line (HR, 1.77; 95% CI, 1.32-2.37; P < .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P < .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P < .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.</p>\",\"PeriodicalId\":9228,\"journal\":{\"name\":\"Blood advances\",\"volume\":\" \",\"pages\":\"3281-3292\"},\"PeriodicalIF\":7.4000,\"publicationDate\":\"2025-07-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood advances\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1182/bloodadvances.2024015415\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024015415","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study.
Abstract: We performed a retrospective multicenter study including 791 patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who underwent autologous stem cell transplantation (ASCT). After a median follow-up of 74 months from infusion, 65% were alive and 84% free of disease. Progression-free survival (PFS) and overall survival (OS) at 6 years were 51% and 63%, respectively. Non-relapse mortality at 1 year was 9%. Age >60 years at ASCT (hazard ratio [HR], 1.31; 95% CI, 1.06-1.62; P = .011), ASCT as ≥3rd line (HR, 1.81; 95% CI, 1.42-2.31; P < .001), and partial response (PR) vs complete response (CR) at ASCT (HR, 1.46; 95% CI. 1.18-1.81; P < .001) were independent variables influencing PFS. Age >60 years at ASCT (HR, 1.62; 95% CI, 1.24-2.12; P < .001), time period before 1 November 2012 (HR, 1.40; 95% CI, 1.07-1.83; P = .014), ASCT as ≥3rd line (HR, 1.77; 95% CI, 1.32-2.37; P < .001), PR vs CR (HR, 1.58; 95% CI, 1.22-2.05; P < .001), and stable disease vs CR pre-ASCT (HR, 3.41; 95% CI, 1.81-6.45; P < .001) were variables associated with worse OS. Refractory/early relapse did not significantly influence survival (6-year PFS and OS in patients with refractory, early, and late relapse were 54% and 64%, 46% and 62%, and 49% and 63%, respectively). To our knowledge, this is the largest series analyzing the efficacy of ASCT in patients with R/R LBCL after rituximab-containing frontline therapy. Our results indicate that ASCT is a curative option for patients with chemosensitive disease.
期刊介绍：
Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016.
Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
